Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Change in Receivables: 2009-2025

Historic Change in Receivables for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $1.7 million.

  • Lifecore Biomedical's Change in Receivables rose 200.72% to $1.7 million in Q2 2025 from the same period last year, while for May 2025 it was $2.3 million, marking a year-over-year decrease of 30.68%. This contributed to the annual value of $2.3 million for FY2025, which is 30.68% down from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical's Change in Receivables is $1.7 million, which was up 29.08% from $1.3 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Change in Receivables ranged from a high of $16.1 million in Q4 2023 and a low of -$11.0 million during Q2 2023.
  • Over the past 3 years, Lifecore Biomedical's median Change in Receivables value was $919,000 (recorded in 2024), while the average stood at -$193,300.
  • As far as peak fluctuations go, Lifecore Biomedical's Change in Receivables soared by 882.08% in 2021, and later slumped by 692.93% in 2023.
  • Lifecore Biomedical's Change in Receivables (Quarterly) stood at $3.5 million in 2021, then tumbled by 251.77% to -$5.2 million in 2022, then skyrocketed by 407.00% to $16.1 million in 2023, then plummeted by 66.52% to $5.4 million in 2024, then spiked by 200.72% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q2 2025, $1.3 million for Q1 2025, and $5.4 million during Q4 2024.